publication date: Jan. 11, 2019
John Mendelsohn understood the urgency of moving discoveries out of the laboratory and into patients
By Margaret L. Kripke
The University of Texas MD Anderson Cancer Center, the city of Houston, and the world of oncology have lost a great leader in Dr. John Mendelsohn, who contributed greatly to his institution, his community, and his field of expertise.
He was a pioneer in the development of anti-receptor antibodies to control tumor growth. He was the first to produce an antibody against the EGF receptor and demonstrate its anti-tumor activity in model systems. This served as a template for the subsequent development of antibodies against a host of growth factor receptors, and many of these are now used to treat a variety of cancers.
Not only was John an accomplished scientist, he was a compassionate and caring physician. These attributes, made him a great role model for physician-scientists. During his tenure, the stature of MD Anderson soared in the area of translational research.
John understood the importance and urgency of moving discoveries out of the laboratory and into patients, and he focused the institution on this goal. He was helped in this mission by his colleague, friend, and tennis partner, Dr. Waun Ki Hong, the former head of the Division of Medicine, whom we also lost earlier this year. Together, they developed the premier translational research effort in cancer in the country, focused on partnerships between staff, clinicians and laboratory scientists.
T. Boone Pickens and John Mendelsohn discuss construction of the T. … Continue reading John Mendelsohn understood the urgency of moving discoveries out of the laboratory and into patients
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.